259 related articles for article (PubMed ID: 36902165)
1. Modified mRNA as a Treatment for Myocardial Infarction.
Wang Y; Wu M; Guo H
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902165
[TBL] [Abstract][Full Text] [Related]
2. Modified mRNA-Mediated
Song MH; Yoo J; Kwon DA; Chepurko E; Cho S; Fargnoli A; Hajjar RJ; Park WJ; Zangi L; Jeong D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892449
[TBL] [Abstract][Full Text] [Related]
3. mRNA-Based Protein Replacement Therapy for the Heart.
Magadum A; Kaur K; Zangi L
Mol Ther; 2019 Apr; 27(4):785-793. PubMed ID: 30611663
[TBL] [Abstract][Full Text] [Related]
4. Delivery of Modified mRNA in a Myocardial Infarction Mouse Model.
Kaur K; Sultana N; Hadas Y; Magadum A; Sharkar MTK; Chepurko E; Zangi L
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597835
[TBL] [Abstract][Full Text] [Related]
5. Modified mRNA Therapeutics for Heart Diseases.
Magadum A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555159
[TBL] [Abstract][Full Text] [Related]
6. Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction.
Huang CL; Leblond AL; Turner EC; Kumar AH; Martin K; Whelan D; O'Sullivan DM; Caplice NM
Mol Pharm; 2015 Mar; 12(3):991-6. PubMed ID: 25588055
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy.
Sultana N; Sharkar MTK; Hadas Y; Chepurko E; Zangi L
Methods Mol Biol; 2021; 2158():281-294. PubMed ID: 32857381
[TBL] [Abstract][Full Text] [Related]
8. Direct reprogramming induces vascular regeneration post muscle ischemic injury.
Kaur K; Hadas Y; Kurian AA; Żak MM; Yoo J; Mahmood A; Girard H; Komargodski R; Io T; Santini MP; Sultana N; Sharkar MTK; Magadum A; Fargnoli A; Yoon S; Chepurko E; Chepurko V; Eliyahu E; Pinto D; Lebeche D; Kovacic JC; Hajjar RJ; Rafii S; Zangi L
Mol Ther; 2021 Oct; 29(10):3042-3058. PubMed ID: 34332145
[TBL] [Abstract][Full Text] [Related]
9. Potential Application of Modified mRNA in Cardiac Regeneration.
Wang AYL; Chang YC; Chen KH; Loh CYY
Cell Transplant; 2024; 33():9636897241248956. PubMed ID: 38715279
[TBL] [Abstract][Full Text] [Related]
10. Modified mRNA as a Therapeutic Tool for the Heart.
Kaur K; Zangi L
Cardiovasc Drugs Ther; 2020 Dec; 34(6):871-880. PubMed ID: 32822006
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Synthesis of Modified mRNA.
Yoo J; Zangi L
Methods Mol Biol; 2022; 2573():77-87. PubMed ID: 36040588
[TBL] [Abstract][Full Text] [Related]
12. Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction.
Hadas Y; Vincek AS; Youssef E; Żak MM; Chepurko E; Sultana N; Sharkar MTK; Guo N; Komargodski R; Kurian AA; Kaur K; Magadum A; Fargnoli A; Katz MG; Hossain N; Kenigsberg E; Dubois NC; Schadt E; Hajjar R; Eliyahu E; Zangi L
Circulation; 2020 Mar; 141(11):916-930. PubMed ID: 31992066
[TBL] [Abstract][Full Text] [Related]
13. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.
Hadas Y; Katz MG; Bridges CR; Zangi L
Wiley Interdiscip Rev Syst Biol Med; 2017 Jan; 9(1):. PubMed ID: 27911047
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Cardiac Delivery of Modified mRNA.
Sultana N; Magadum A; Hadas Y; Kondrat J; Singh N; Youssef E; Calderon D; Chepurko E; Dubois N; Hajjar RJ; Zangi L
Mol Ther; 2017 Jun; 25(6):1306-1315. PubMed ID: 28389322
[TBL] [Abstract][Full Text] [Related]
15. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.
Zangi L; Lui KO; von Gise A; Ma Q; Ebina W; Ptaszek LM; Später D; Xu H; Tabebordbar M; Gorbatov R; Sena B; Nahrendorf M; Briscoe DM; Li RA; Wagers AJ; Rossi DJ; Pu WT; Chien KR
Nat Biotechnol; 2013 Oct; 31(10):898-907. PubMed ID: 24013197
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction.
Shafei AE; Ali MA; Ghanem HG; Shehata AI; Abdelgawad AA; Handal HR; Talaat KA; Ashaal AE; El-Shal AS
J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29044850
[TBL] [Abstract][Full Text] [Related]
17. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration.
Labonia MCI; Estapé Senti M; van der Kraak PH; Brans MAD; Dokter I; Streef TJ; Smits AM; Deshantri AK; de Jager SCA; Schiffelers RM; Sluijter JPG; Vader P
J Control Release; 2024 May; 369():734-745. PubMed ID: 38604385
[TBL] [Abstract][Full Text] [Related]
18. Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression.
Turnbull IC; Eltoukhy AA; Fish KM; Nonnenmacher M; Ishikawa K; Chen J; Hajjar RJ; Anderson DG; Costa KD
Mol Ther; 2016 Feb; 24(1):66-75. PubMed ID: 26471463
[TBL] [Abstract][Full Text] [Related]
19. Optimization of 5' Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury.
Sultana N; Hadas Y; Sharkar MTK; Kaur K; Magadum A; Kurian AA; Hossain N; Alburquerque B; Ahmed S; Chepurko E; Zangi L
Mol Ther Methods Clin Dev; 2020 Jun; 17():622-633. PubMed ID: 32300609
[TBL] [Abstract][Full Text] [Related]
20. Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia.
Yu Z; Witman N; Wang W; Li D; Yan B; Deng M; Wang X; Wang H; Zhou G; Liu W; Sahara M; Cao Y; Fritsche-Danielson R; Zhang W; Fu W; Chien KR
J Control Release; 2019 Sep; 310():103-114. PubMed ID: 31425721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
